Is Lannett Co (LCI) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Lannett Co (LCI) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Lannett Co is one of 889 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. LCI is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for LCI's full-year earnings has moved 25.50% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, LCI has moved about 135.68% on a year-to-date basis. In comparison, Medical companies have returned an average of 0.11%. This means that Lannett Co is performing better than its sector in terms of year-to-date returns.
Looking more specifically, LCI belongs to the Medical - Drugs industry, which includes 178 individual stocks and currently sits at #55 in the Zacks Industry Rank. Stocks in this group have gained about 0.91% so far this year, so LCI is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to LCI as it looks to continue its solid performance.
Click to get this free report
Lannett Co Inc (LCI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.